Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Gilead Sciences (GILD) Gets a Buy from Cantor Fitzgerald

Tipranks - Tipranks - Wed Apr 8, 12:18PM CDT

Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences on April 5 and set a price target of $155.00.

Easter Sale - 70% Off TipRanks

According to TipRanks, Gould is a 4-star analyst with an average return of 5.9% and a 51.76% success rate. Gould covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Pfizer.

In addition to Cantor Fitzgerald, Gilead Sciences also received a Buy from Bernstein’s Courtney Breen in a report issued on April 3. However, today, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See Insiders’ Hot Stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).